

AGENDA

***Uniform Formulary Beneficiary Advisory Panel (BAP)
01 April 2020 @ 12:00 PM Eastern Daylight Time (Note new meeting time)***

Virtual Meeting

- **Administrative Meeting starts at 11:00 AM Eastern Daylight Time**
- **Sign-In**
- **Roll Call**
- **Welcome and Opening Remarks**
- **Therapeutic Class Reviews**

Members of the DHA Pharmacy Operations Division (POD) Formulary Management Branch (FMB) will present relative clinical and cost-effective analyses along with the DoD Pharmacy & Therapeutics Committee (P&T) recommendations for the Uniform Formulary (UF) and any recommended Tier 4/Not Covered candidates.

The P&T Committee made recommendations for the following drugs/drug classes during the February 2020 meeting:

- **Drug Class Reviews**
 - *Pain Agents: Nonsteroidal Anti-Inflammatory Drug (NSAID) Subclass*
 - *Pain Agents: Topical Pain Subclass*
- **Newly Approved Drugs per 32 CFR 199.21(g)(5)**
 - *albuterol dry powder inhaler (ProAir Digihaler) — Pulmonary-1: Short Acting Beta Agonist (SABA) for asthma*
 - *asenapine transdermal system (Secuado) — New patch formulation of asenapine for schizophrenia in adults*
 - *baclofen oral solution (Ozobax) — New oral solution formulation of baclofen for spasticity associated with multiple sclerosis*
 - *benralizumab injection (Fasenra Pen) — Miscellaneous Pulmonary I Agent in a new formulation of a self-administered pen for eosinophilic and severe asthma*
 - *benzoyl peroxide 9.8% foam (Enzoclear) — Keratolytic for acne vulgaris*
 - *colchicine oral solution (Gloperba) — Anti-Gout Agent in a new oral solution formulation of colchicine*

- *diroximel fumarate (Vumerity) —Multiple Sclerosis Agents; a new methyl fumarate formulation*
- *elexacaftor/tezacaftor/ivacaftor (Trikafta) —Cystic Fibrosis triple fixed-dose combination*
- *minocycline 4% foam (Amzeeq) — Topical Acne and Rosacea Agents; new formulation of minocycline*
- *omeprazole magnesium/amoxicillin/rifabutin (Talicia) - Miscellaneous Anti-infective for Helicobacter pylori salvage therapy*
- *pegfilgrastim-bmez injection (Ziextenzo) — Hematological Agents: White Blood Cell Stimulants; another biosimilar for Neulasta*
- *pretomanid — Antitubercular drug for extensively drug resistant tuberculosis (XDR TB)*
- *testosterone undecanoate capsules (Jatenzo) — Testosterone Replacement Therapy (TRT)*
- *trifarotene 0.005% cream (Aklief) — Topical Acne and Rosacea Agents in a new retinoid formulation*
- *voxelotor (Oxbryta) — Sickle cell anemia agent for sickle cell disease*
- *zanubrutinib (Brukinsa) — Oral oncologic agent for mantle cell lymphoma*

➤ **Utilization Management Issues**

➤ **Prior Authorization Criteria—New Manual PA Criteria**

- *Acne: Topical Acne and Rosacea subclass—Sulfacetamide and sulfacetamide/sulfur products*
- *Antidepressants and Non-opioid Pain Syndrome Agents—Venlafaxine hydrochloride (HCL) ER 37.5 mg, 75 mg, 150 mg, and 225 mg tablets*
- *Vitamin: Prenatal—Prenatal vitamin (Zalvit)*
- *Insulins: Rapid Acting Agents—generic insulin aspart (authorized generic for Novolog)*
- *Respiratory Agents Miscellaneous—epinephrine auto injector (Auvi-Q)*

➤ **Prior Authorization Criteria—Updated PA**

- *Migraine Agents: Calcitonin Gene-related Peptide (CGRP) Preventatives—erenumab-aooe (Aimovig), fremanezumab-vfrm (Ajovy), and galcanezumab-gnlm (Emgality)*
- *Antilipidemic 2's-omega-3 fatty acids: icosapent ethyl (Vascepa)*
- *Targeted Immunomodulatory Biologics (TIBs): tofacitinib (Xeljanz XR)*
- *Pulmonary 1's-Pulmonary Miscellaneous: mepolizumab (Nucala)*
- *Basal Insulins: insulin glargine U-300 (Toujeo)*
- *Corticosteroids: Immune Modulators—deflazacort (Emflaza)*
- *Acne Agents: Tetracyclines—doxycycline monohydrate IR/ER 40 mg capsules (Oracea)*

➤ **Re-Evaluation of NF Generics**

- *Antidepressant-1s (AD-1s) and Non-Opioid Pain Syndrome Drugs: pregabalin (Lyrica)*
- *AD-1s: Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs): desvenlafaxine succinate ER (Pristiq) and desvenlafaxine ER*

➤ **Items for Information: Prenatal Legend Vitamins Moving to OTC Status**

➤ **Panel Discussions**

The Beneficiary Advisory Panel members will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will discuss the recommendations and vote to accept or reject them. The Panel will provide comments on their vote as directed by the Panel Chairman.